Large pharmaceutical company uses D360 data informatics technology to advance its neurological discovery program
D360 provides data access in real time enabling scientists to make informed decisions.
Preclinical research at a large-size pharmaceutical company strives to discover novel agents to modulate disease states by restoration of or enhancing target functions in neurological disease. With a heavy focus on understanding human biology and high-dimensional genetic data, the company relies on collaborative cutting-edge technology platforms that integrate structural biology, chemical biology, computational chemistry, novel assay development, and compound screening automation to translate findings to benefits for patients. Thus, being able to analyze large volumes of data from multiple internal databases and registries as well as from external collaborators (academic labs and consortia) in real time is essential for the company’s drug discovery process. Multi-disciplinary teams need to communicate updates quickly to leadership so that go/no-go decisions on agents can be made and agents with the highest likelihood of success can move on to the next stage of drug development. The company had an older data analysis platform in place since 2006, but in 2017 found that this platform could not keep up with current demands for collaboration and the needs of discovery scientists.
Everyone wants their data and others’ data to be in D360 to review data and to understand the science. D360 appeals to all user types because of it’s intuitive user interface and ease of use.